Genzyme Corporation's LEMTRADA™ (alemtuzumab) Application for MS Accepted for Review by the FDA

Published: Jan 28, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADA (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS). The company also reported key highlights from the U.S. launch of once-daily, oral AUBAGIO (teriflunomide).

Back to news